

Date: 18th November, 2022

BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	5 th Floor, Exchange Plaza,
Dalal Street	Bandra Kurla Complex Bandra (East)
Mumbai – 400 001	Mumbai-400051
Script Code: 539872	Script Code: BAJAJHCARE

Dear Sir,

Sub: Business Updates- successfully completed first ever pre-approval inspection of United State Food and Drug Administration (USFDA) of its API facility located at Vadodara, Gujarat

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates - successfully completed first ever pre-approval inspection of United State Food and Drug Administration (USFDA) of its API facility located at Vadodara, Gujarat.

Kindly take the same on record.

Thanking you,

For and on behalf of Board of Directors of Bajaj Healthcare Limited

Aakash Keshari Company Secretary

Encl: a/a



BAJAJ HEALTHCARE LIMITED CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West, Maharashtra – 400604.

BUSINESS UPDATE

Bajaj Healthcare Ltd.("BHL") announces successfully completed first ever pre-approval inspection of United State Food and Drug Administration (USFDA) of its API facility located at Vadodara, Gujarat.

Thane, 18th November, 2022: Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, announces successfully completed first ever pre approval inspection of United State Food and Drug Administration (USFDA) of its API facility located at Vadodara, Gujarat.

BHL is pleased to inform you that, US Food and drug administration (USFDA) has conducted it's pre approval inspection of its API facility located at Vadodara, Gujarat from November 14, 2022 to November 17,2022. The pre-approval inspection of United State Food and Drug Administration (USFDA) has completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited.

Commenting on the above business update, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "I am happy to announce that we successfully completed first ever pre approval USFDA inspection with ZERO 483 observation at our API Manufacturing facilities located at Vadodara, Gujarat. We are committed to strict adherence to all applicable guidelines and regulations and maintaining the highest quality standards in delivering quality services and timely delivery to our clients."

About Bajaj Healthcare Limited

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

For further information on the Company, please visit www.bajajhealth.com

Rupesh Nikam (CFO) **Bajaj Healthcare Limited**

Contact: +91 22 6617 7400

Email: investors@bajajhealth.com

Krunal Shah/ Vinayak Shirodkar Captive IR Strategic Advisors Pvt. Ltd.

Contact: +91 9372467194

Email: krunal@cap-ir.com / Vinayak@cap-ir.com

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE